|Application ||WB, LCI|
|Calculated MW||52845 Da|
|Homology||Human - identical; mouse - 15/16 amino acid residues identical.|
|Other Names||Cannabinoid receptor 1, CB-R, CB1, Brain-type cannabinoid receptor, Cnr1, Skr6|
|Related products for control experiments||Control peptide antigen (supplied with the antibody free of charge).|
|Target/Specificity||Peptide NKSLSSFKENEENIQC, corresponding to amino acid residues 84-99 of rat CB1 receptor (Accession P20272). Extracellular, N-terminus.|
|Peptide Confirmation||Confirmed by amino acid analysis.|
|Format||Affinity purified antibody, lyophilized powder|
|Reconstitution||50 µl or 0.2 ml deionized water, depending on the sample size.|
|Antibody Concentration After Reconstitution||0.7 mg/ml.|
|Buffer After Reconstitution||Phosphate buffered saline (PBS), pH 7.4, 1% BSA, 0.05% NaN3.|
|Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Storage After Reconstitution||The reconstituted solution can be stored at 4ºC for up to 2 weeks. For longer periods, small aliquots should be stored at -20ºC or below. Avoid multiple freezing and thawing. The further dilutions should be made using a carrier protein such as BSA (1%). Centrifuge all antibody preparations before use (10000 × g 5 min).|
|Control Antigen Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Control Antigen Reconstitution||100 µl water.|
|Control Antigen Storage After Reconstitution||-20ºC.|
|Preadsorption Control||1 µg peptide per 1 µg antibody.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Cannabinoids have been used in eastern medicine for many years as pain relievers.1 Δ9-tetrahydrocannabinol (THC), the major psychoactive compound in marijuana and hashish, has been shown to interact with two specific cannabinoid receptors: cannabinoid receptor 1 (CB1 Receptor or CB1R) and cannabinoid receptor 2 (CB2 Receptor or CB2R).2 The cannabinoid receptors can be distinguished by their amino acid sequences, signaling mechanisms, and tissue distributions.2 Both receptors belong to the G-protein-coupled receptor (GPCR) superfamily. CB1R was shown to modulate several Ca2+ and K+ ion channels.2,3 CB1R is primarily expressed in the central nervous system. However, expression of CB1R is also detected in the peripheral terminals, in non-neuronal peripheral tissues such as uterus, testes, spleen, as well as in cells of the immune system.3,4 CB1R is implicated in many cellular functions such as neurotransmitter release, pain relief, cancer, and obesity.5,6 Growth inhibition of tumor cells was demonstrated following mixed CB1R/CB2R agonist treatment in both prostate and non-melanoma skin cancers.5,6 Through their interaction with CB1R, cannabinoid compounds stimulate appetite for sweets and palatable foods in particular, making CB1R an attractive therapeutic target for the treatment of obesity and eating disorders.7 Alomone is pleased to offer a new extracellular antibody directed against the rat CB1 receptor. Anti-Cannabinoid Receptor 1 (extracellular) antibody (#AG1300) can be used in western blot and immunohistochemistry applications, and recognizes CB1R in mouse and rat samples.
References 1. Brooks, J.W. and Fraquhar-Smith, M.A. (2003) Br. J. Anaesth. 3, 175. 2. Howlett, A.C. (2002) Prostaglandins Other Lipid Mediat. 68–69, 619. 3. Howlett, A.C. et al. (2002) Pharmacol. Rev. 54, 161. 4. Rueda, D. et al. (2000) Mol. Pharmacol. 58, 814. 5. Sarfaraz, S. et al. (2005) Cancer Res. 65, 1635. 6. Casanova, M.L. et al. (2003) J. Clin. Invest. 111, 43. 7. Cota, D. et al. (2003) Int. J. Obes. Relat. Metab. Disord. 27, 289.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.